HOME >> BIOLOGY >> NEWS
New algorithms classify outcomes of nonsmall cell lung cancer patients

Two research teams have developed models for classifying the clinical outcomes of patients with nonsmall-cell lung cancer (NSCLC) using mass spectrometry techniques. The studies are published in the June 6 Journal of the National Cancer Institute.

Currently, clinicians do not have adequate methods for determining the prognosis of patients with NSCLC or for determining which patients will benefit from treatment with certain drugs. The new models could help physicians decide who will benefit from certain treatment options.

In one study, an international team led by David Carbone, M.D., Ph.D., of the Vanderbilt-Ingram Cancer Center in Nashville, developed an algorithm to predict the outcomes of NSCLC patients treated with the drugs gefitinib and erlotinib, two tyrosine kinase inhibitors. The algorithm places patients into categories indicating good or poor survival before treatment with one of the drugs and is based on the pattern of a group of proteins in the patients blood serum. The authors developed the algorithm on a group of patients with known outcomes then tested it on pretreatment serum for independent validation and control groups.

The researchers found that the algorithm could classify patients by their survival outcomes after treatment. In one validation group, patients who were predicted to have good outcomes survived for a median of 306 days, while those in the poor group survived a median of 107 days. By contrast, the algorithm did not correctly classify patients in control groups, who were not treated with the drug.

In the clinical development of biomarkers for the individualization of therapy, it is important to distinguish between those that can accurately classify patients according to whether they will benefit from an intervention and those that simply portend a favorable or unfavorable prognosis, independent of the planned intervention. Biomarkers predictive for survival benefit from an intervent
'"/>

Contact: Liz Savage
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
5-Jun-2007


Page: 1 2

Related biology news :

1. Skin rash actually signifies better outcomes for pancreatic and lung cancer patients
2. Improving outcomes in premature births
3. Delay in use of nevirapine-based AIDS treatment can improve outcomes
4. Walgreens and Joslin Diabetes Center form broad alliance to improve diabetes outcomes
5. Cell-regulating gene may predict survival outcomes for breast cancer patients
6. Gene signature assesses breast cancer outcomes
7. Signature of chromosome instability predicts cancer outcomes
8. Fitness level affects bariatric surgery outcomes
9. Chromosomal tests can determine brain tumor therapy, outcomes, Jefferson oncologists find
10. Patient outcomes linked to biomarker levels by quantitative technology
11. Gene at heart of bad outcomes in high blood pressure patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2020)... ... ... In an upcoming episode scheduled for the fall of 2020, Advancements with Ted ... local listings for more info. , Today, the majority of testing is performed at ... the country. Results are then available several days later. Now, in an effort to ...
(Date:6/23/2020)... ... June 23, 2020 , ... First Aid ... Ltd, a UK supplier and manufacturer of innovative portable renewable energy equipment, have ... the fight against the COVID-19 pandemic in Zambia. , One of Renovagen’s FAST ...
(Date:6/23/2020)... ... 23, 2020 , ... In its June 22 online post, business and technology ... Sherley, M.D., Ph.D., founder and director of stem cell biotechnology company Asymmetrex . ... that starting July 5 it would begin offering free tissue stem cell ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... July 16, 2020 , ... ... in the early detection and prevention of high-burden diseases, and Centric Consulting, a ... and healthcare organizations to utilize existing data in order to identify and prioritize ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... of Technology (MIT) has expanded the company’s exclusive license to include clinical ... the point-of-care diagnostic market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ ...
(Date:7/7/2020)... ... July 06, 2020 , ... R3 International is now offering stem ... 200 million stem cells. Depending on the patient's condition, treatment may be offered IV, ... die having some form of Alzheimers dementia, and the incidence continues to increase as ...
(Date:7/1/2020)... ... June 29, 2020 , ... The Interlocal Purchasing System (TIPS), ... membership, recently named BioFit Engineered Products an Awarded Vendor. Awarded Vendor ... seating, cafeteria tables, book trucks and carts at discounted pricing without the delay ...
Breaking Biology Technology:
Cached News: